...
vinc-img

Vincerx Pharma Inc, Common Stock

VINC

NAQ

$0.1926

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$10.48M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
483.97K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.18 L
$9.37 H
$0.1926

About Vincerx Pharma Inc, Common Stock

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVINCSectorS&P500
1-Week Return-12.22%-3.72%-0.05%
1-Month Return-30.14%-1.85%2.75%
3-Month Return-72.48%-11.4%7.4%
6-Month Return-70.19%-4.41%10.47%
1-Year Return-69.18%4.13%27.57%
3-Year Return-98.06%0.3%29.56%
5-Year Return-97.94%36.62%89.3%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-173.00K340.00K939.00K915.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":18.42,"profit":true},{"date":"2021-12-31","value":36.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.44,"profit":true}]
Gross Profit-(173.00K)(340.00K)(939.00K)(915.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-17299600,"profit":false},{"date":"2021-12-31","value":-34000000,"profit":false},{"date":"2022-12-31","value":-93900000,"profit":false},{"date":"2023-12-31","value":-91500000,"profit":false}]
Gross Margin-(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses45.00K10.71M62.66M71.11M42.61M[{"date":"2019-12-31","value":0.06,"profit":true},{"date":"2020-12-31","value":15.07,"profit":true},{"date":"2021-12-31","value":88.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.92,"profit":true}]
Operating Income(45.00K)(10.71M)(62.66M)(73.57M)(42.61M)[{"date":"2019-12-31","value":-4500000,"profit":false},{"date":"2020-12-31","value":-1071400000,"profit":false},{"date":"2021-12-31","value":-6265600000,"profit":false},{"date":"2022-12-31","value":-7357400000,"profit":false},{"date":"2023-12-31","value":-4260900000,"profit":false}]
Total Non-Operating Income/Expense-(16.00K)23.35M8.87M3.96M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.07,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":37.99,"profit":true},{"date":"2023-12-31","value":16.98,"profit":true}]
Pre-Tax Income(45.00K)(10.72M)(39.31M)(65.37M)(40.16M)[{"date":"2019-12-31","value":-4500000,"profit":false},{"date":"2020-12-31","value":-1072200000,"profit":false},{"date":"2021-12-31","value":-3930600000,"profit":false},{"date":"2022-12-31","value":-6536700000,"profit":false},{"date":"2023-12-31","value":-4015700000,"profit":false}]
Income Taxes(54.00)8.00K(23.70M)(8.21M)-[{"date":"2019-12-31","value":-0.68,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-296225,"profit":false},{"date":"2022-12-31","value":-102587.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes-(10.73M)(15.61M)(57.16M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1073000000,"profit":false},{"date":"2021-12-31","value":-1560800000,"profit":false},{"date":"2022-12-31","value":-5716000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations-(10.72M)(39.31M)(65.37M)(48.85M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1072200000,"profit":false},{"date":"2021-12-31","value":-3930600000,"profit":false},{"date":"2022-12-31","value":-6536700000,"profit":false},{"date":"2023-12-31","value":-4885000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(45.00K)(10.73M)(15.61M)(57.16M)(40.16M)[{"date":"2019-12-31","value":-4500000,"profit":false},{"date":"2020-12-31","value":-1073000000,"profit":false},{"date":"2021-12-31","value":-1560800000,"profit":false},{"date":"2022-12-31","value":-5716000000,"profit":false},{"date":"2023-12-31","value":-4015700000,"profit":false}]
EPS (Diluted)(0.00)(2.38)(2.28)(3.12)(1.89)[{"date":"2019-12-31","value":-0.2,"profit":false},{"date":"2020-12-31","value":-238,"profit":false},{"date":"2021-12-31","value":-228,"profit":false},{"date":"2022-12-31","value":-312,"profit":false},{"date":"2023-12-31","value":-189,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VINC
Cash Ratio 1.86
Current Ratio 2.17

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VINC
ROA (LTM) -65.99%
ROE (LTM) -142.45%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VINC
Debt Ratio Lower is generally better. Negative is bad. 0.39
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.61

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VINC
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.71
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Vincerx Pharma Inc share price today?

Vincerx Pharma Inc (VINC) share price today is $0.1926

Can Indians buy Vincerx Pharma Inc shares?

Yes, Indians can buy shares of Vincerx Pharma Inc (VINC) on Vested. To buy Vincerx Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VINC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Vincerx Pharma Inc be purchased?

Yes, you can purchase fractional shares of Vincerx Pharma Inc (VINC) via the Vested app. You can start investing in Vincerx Pharma Inc (VINC) with a minimum investment of $1.

How to invest in Vincerx Pharma Inc shares from India?

You can invest in shares of Vincerx Pharma Inc (VINC) via Vested in three simple steps:

  • Click on Sign Up or Invest in VINC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Vincerx Pharma Inc shares
What is Vincerx Pharma Inc 52-week high and low stock price?

The 52-week high price of Vincerx Pharma Inc (VINC) is $9.37. The 52-week low price of Vincerx Pharma Inc (VINC) is $0.18.

What is Vincerx Pharma Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Vincerx Pharma Inc (VINC) is

What is Vincerx Pharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Vincerx Pharma Inc (VINC) is 0.71

What is Vincerx Pharma Inc dividend yield?

The dividend yield of Vincerx Pharma Inc (VINC) is 0.00%

What is the Market Cap of Vincerx Pharma Inc?

The market capitalization of Vincerx Pharma Inc (VINC) is $10.48M

What is Vincerx Pharma Inc’s stock symbol?

The stock symbol (or ticker) of Vincerx Pharma Inc is VINC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top